secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K/A
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027367
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY
----------------------------------------------------------------------

- Revenue $12.3M, down ~3.1% YoY from $12.8M.
- Operating income $30K vs $585K; net loss $35K vs net income $516K.
- Diluted EPS $0.00 per share vs $0.02 in prior-year quarter.
- Co-CEOs cite customer overstocking from pandemic as reason for sales decline.
- Two largest customers in Contract Manufacturing segment made up 85% of revenue (91% a year ago).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/0001437749-22-027367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/inbp20221114_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer